Phase II/III Market Outlook: 2020-2024

$4,460.00$8,920.00

Licensing Options

  • SINGLE-USER LICENSE

    A Single-User License allows access to an individual user.

  • ENTERPRISE-WIDE LICENSE

    An Enterprise-Wide License allows access to all employees and sites within an organization.

Report Overview

Welcome to ISR’s Phase II/III Study Trends and Market Outlook (2020-2024) report. The goal of this report is to provide readers with a high-level view of the Phase II/III clinical development space to illustrate current market dynamics and inform strategic planning. For this report, 146 Phase II/III decision-makers were surveyed to share their insights into where the Phase II/III market is now and what changes they expect over the next four years. Current and predicted study spend and outsourcing proportions are key pieces of information with which sponsors and service providers should be familiar. Additionally, as the use of service providers is ubiquitous in the clinical development world, it is important to have a good grasp on the landscape of service provider selection. Finally, staying on top of trends such as use of risk-based monitoring, use of activity trackers, and how companies are responding to the COVID-19 pandemic helps readers stay current with market happenings and plan for what the market is expected to look like in 2024.

 

What you will learn:

  • 4-year examination of the industry’s Phase II/III market dynamics (e.g. study volume, outsourced spend); including respondent rationale for their predictions
  • How Phase II/III spend is divided between large CROs, mid-size CROs, small/niche CROs, and AMCs – how this varies by sponsor size and how it is expected to change over time
  • Average dollar value of outsourced Phase II/III studies and the dollar value of studies respondents are comfortable awarding to each provider type
  • Which roles have the most responsibility for each of six different decisions related to Phase II/III study outsourcing
  • Evolution of trends in the Phase II/III market (e.g. expansion into developing markets, responses to the COVID-19 pandemic, and use of methods such as Real-World Evidence, patient centricity, non-traditional monitoring, ePRO, sensors/patches, and activity trackers, etc.)

How pharma can use this report:

  • Use the predictions of your peers to identify in what types of studies your competition is investing resources and understand how your company’s strategy compares to that of the industry
  • Ensure your Phase II/III outsourcing practices are industry standard or better

How CROs can use this report:

  • Utilize this information to ensure your capabilities and capacity are in line with the study types and volume that will be needed in the near future
  • Gain understanding of the key decision-makers within sponsor organizations to develop more targeted communications
  • Learn the most desirable characteristics of a Phase II/III service provider

 

Major Topics:

  • Market Dynamics
  • Provider Perceptions and Selection
  • Trends and Predictions
  • Study Data

Questions?

Our team is here to help.

For questions about syndicated report purchases, custom research solutions, or other billing-related topics, please contact sales@ISRreports.com.